One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Trillium Therapeutics Inc. logo
Trillium Therapeutics Inc. TRIL

Trillium Therapeutics Inc. Balance Sheet 2020-2011 | TRIL

Brief balance sheet overview of Trillium Therapeutics Inc.

The comparison uses five available annual reports from the 2016–2020 interval.

Total assets increased by +500.5%, from $50.1 million to $300.8 million. A CAGR near 56.5% points to substantial expansion.

Liabilities grew more slowly than assets: +243.7% versus +500.5%. Expansion relied more on equity, improving funding quality.

Net debt moved below zero to -$246.8 million, reflecting surplus cash over debt.

The balance sheet carries negative retained earnings of -$249.4 million. The figure may result from accumulated losses or an active capital return policy.

Overall assessment

Trillium Therapeutics Inc.'s financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Trillium Therapeutics Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-247 M -14.6 M -15.3 M -21.3 M -37.8 M -86.5 M -25.9 M -30.2 M -1.38 M -2.64 M

Long Term Debt

- - - 73.7 K 143 K 270 K 280 K 321 K - -

Total Non Current Liabilities

557 K 12 M 371 K 982 K 1.95 M 680 K 350 K 419 K - -

Total Current Liabilities

21.4 M 13.5 M 9.82 M 10.9 M 4.45 M 3.56 M 3.53 M 688 K 186 K 347 K

Total Liabilities

22 M 25.6 M 10.2 M 11.9 M 6.39 M 4.24 M 3.88 M 1.11 M 186 K 347 K

Retained Earnings

-249 M -191 M -149 M -102 M -67.8 M -58.4 M -41.3 M -35.4 M -33.6 M -31.7 M

Total Assets

301 M 25.4 M 40.8 M 71 M 50.1 M 90 M 28.2 M 33 M 1.58 M 2.71 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Trillium Therapeutics Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Certara Certara
CERT
$ 10.56 -1.12 % $ 1.69 B usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
$ 13.26 -0.15 % $ 190 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.23 -52.81 % $ 1.5 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.68 -4.63 % $ 171 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.59 -5.92 % $ 2.08 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 63.61 -2.11 % $ 6.61 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
Genprex Genprex
GNPX
$ 1.46 -12.87 % $ 1.36 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 30.23 -7.1 % $ 510 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 0.87 -7.57 % $ 77.9 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.42 -1.64 % $ 11.6 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 7.6 -4.82 % $ 220 M usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.38 -5.66 % $ 40.4 M canadaCanada
Lipocine Lipocine
LPCN
$ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.89 -5.56 % $ 227 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
$ 0.25 -13.67 % $ 2.72 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
$ 0.77 4.74 % $ 241 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.35 -10.37 % $ 33.6 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.53 -8.68 % $ 555 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 7.73 -2.59 % $ 9.16 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
$ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
$ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 15.62 -1.01 % $ 1.68 B usaUSA
Replimune Group Replimune Group
REPL
$ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
$ 6.62 -2.43 % $ 35.2 M usaUSA